Information Provided By: 
Fly News Breaks for January 24, 2018
HBIO
Jan 24, 2018 | 09:23 EDT
Janney Capital analyst Paul Knight said Harvard Bioscience has become a preclinical and early stage research pure play by selling its Denville Scienctific labware distribution business and acquiring Data Sciences International. Given these changes, the company should be more closely linked to the robust growth in clinical trial activity, said Knight, who raised his fair value estimate on Harvard Bioscience to $8 from $5. He keeps a Buy rating on the stock.
News For HBIO From the Last 2 Days
There are no results for your query HBIO
